[ad_1]
The full results of a clinical trial for the Pfizer-BioNTech Covid-19 vaccine were published in the New England Journal of Medicine on Thursday. A commission from the US Food and Drug Administration met to discuss its approval, BGNES reported.
Prof. Angelov: Claims that the vaccine poses health risks are false
An editorial related to the scientific article states: “The test results are impressive enough to withstand any possible analysis. This is a triumph.” The full study included nearly 44,000 volunteers, several thousand more than in previous analyzes.
About half received the vaccine and the other half acted as a placebo. Two-dose BNT162b2 regimen confirmed gives 95 percent efficiency to prevent COVID-19 infection.
What are the possible side effects of the COVID-19 vaccine?
The vaccine worked the same way, regardless of “age, gender, race, ethnicity, baseline body mass index, and the presence of coexisting conditions,” according to the New England Journal of Medicine.
Of the 10 severe COVID-19 cases after the first dose, nine occurred in placebo recipients and one in a vaccinated person. The editorial accompanying the study pointed to some “minor problems.”
“The number of severe COVID-19 cases (one in the vaccinated group and nine in the placebo group) is too small to draw conclusions about whether the rare cases that occur in vaccinated people are actually more severe.” says the message.
COVID-19 MUTATIONS: The vaccine is effective regardless of the form of the virus.
Other questions include whether unexpected safety concerns can arise when the number of people vaccinated swells to millions and possibly billions.
It is also unknown whether more side effects will occur with longer follow-up, how long the vaccine will remain effective, whether it will limit transmission, and how it will work in children, pregnant women, and immunosuppressed patients.
To be the first to know the news from Bulgaria and the world, download the new NOVA app – for Android HERE or iOS (Apple) HERE.
Subscribe FREE to the nova.bg newsletter HEREto receive the most important news of the day in your email.
[ad_2]
